Researchers have used human embryonic stem cells to create a new model system that allows them to study the initiation and progression of small cell lung cancer (SCLC).

A new method developed by scientists is likely to speed the study of an important biological process called ADP-ribosylation.ADP-ribosylation occurs at high levels in some cancers, and drugs called PARP (ADP-ribose polymerase) inhibitors, which block ADP-ribosylation, comprise one of the most promising new classes of cancer therapy.

The MYCN oncogene has long been known to be a key cause of a number of deadly solid tumour cancers, including neuroblastoma, which claims more lives of children under the age of 5 than any other cancer.

Some types of cancer cannot be treated with classical chemotherapy. Scientists are currently working on a metallorganic molecule as an anti-tumour drug. Their research has given thorough insights into its mechanism in attacking cancer cells.

Children born after assisted reproductive technology (ART) do not appear to be at greater risk of developing cancer than other children, according to the first study to look at the long-term cancer risk in ART children compared to those in the general population or who were naturally conceived by subfertile women.

In a pair of new studies, researchers from Roswell Park Comprehensive Cancer Center outline strategies for overcoming pancreatic cancer’s resistance to treatment through approaches that exploit this cancer’s reliance on uncontrolled, or deregulated, cell proliferation.

Researchers have identified checkpoint inhibitor resistance mechanisms in many solid tumour cancers, including melanoma, lung cancer and breast cancer.

An engineered virus kills cancer cells more effectively than another virus currently used in treatments, according to Hokkaido University researchers. The virus, called dl355, has an even stronger anticancer effect than another engineered virus currently used in clinical practice

Chemotherapy and radiation are effective cancer treatments because they kill rapidly dividing cells, including tumour cells. But for children, whose tiny bodies are still growing – these treatments can cause lifelong damage. Now, scientists have reported that a targeted therapy that blocks a protein called LSD1 was able to shrink tumours in mice with a form of pediatric brain cancer known as medulloblastoma.